Phase 3: Acute Muscle Spasm Study

1,000 patients

18 - 64 years

Numerical Rating Scale

(NRS) pain "right now" Primary Endpoint

1:1:1:1 Randomization

Primary Endpoint Day 14

Study initiated Q4 2020,

Topline data Q4 2021

Subject-rated Pain

(NRS)

Placebo

200 mg TID

100 mg TID

50 mg TID 

RANDOMIZATION

1

4

DAY

14

21

Screening & Enrollment

(-3 to 0 Days)

Subject-Rated Pain Numerical Rating Scale (NRS) on Day 1, 4, 14
Daily ePRO Assessments and Dosing Diary 

Follow-up